secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2023-04-05T23:59:59+00:00
Accession:  0001193125-23-091620
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics CFO Esther Rajavelu resigns effective April 21, 2023
-------------------------------------------------------------------------

- CFO Esther Rajavelu resigns effective April 21, 2023 to pursue another opportunity.
- Company will conduct an executive search for a new chief financial officer.
- Rajavelu enters consulting agreement for up to 3 months; receives $52,780/month plus $6,000 initiation fee.
- Vested stock option exercise period extended to 12 months after consulting services end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312523091620/0001193125-23-091620-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312523091620/d471861d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-091620

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer